BioventusvsJohnson & Johnson

BVS and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

BVS

Bioventus Inc.

$10.46

Value $697M

-1.84%
BVS's page

Bioventus (BVS) has a market value of $697M and Johnson & Johnson (JNJ) $681B. Over the last year, with dividends, BVS moved +39.3% and JNJ +50.3%. Dividend yield: BVS none, JNJ 1.87%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BVS$697M

    JNJ$681B

    JNJ is 977 times BVS

  • Revenue, 12 months

    BVS$586M

    JNJ$99.3B

    JNJ is 170 times BVS

  • Net income, 12 months

    BVS$57M

    JNJ$16.1B

    JNJ is 281 times BVS

  • Operating margin

    BVS9.7%

    JNJ–

  • ROIC

    BVS9.4%

    JNJ12.4%

    3.0 points apart

  • P/E

    BVS–

    JNJ42.3

  • Dividend yield

    BVS0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    BVS-32.7%

    JNJ+99.1%

    131.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BVS-32.7%

JNJ+99.1%

010020020222023202420252026
Returns by period
PeriodBVSWith dividendsJNJWith dividends
1 year since November 12, 2025+39.3%Price +39.3%+50.3%Price +47.0%
3 years since November 13, 2023+188.1%+42.3% a yearPrice +188.1%+110.8%+28.2% a yearPrice +93.6%
5 years since November 12, 2021-32.7%-7.6% a yearPrice -32.7%+99.1%+14.8% a yearPrice +73.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BVSBioventusJNJJohnson & Johnson

Valuation

BVSJNJ
Valuation
Price$10.46$282.55
Market value$697M$681B
Enterprise value (EV)$905M$708B
P/E–42.3
P/E, 5-year median–21.9
P/B2.98.4
EV/EBIT16.039.9
Free cash flow yield12.2%3.0%

Results and growth

BVSJNJ
Results and growth
Revenue, 12 months$586M$99.3B
Net income, 12 months$57M$16.1B
Free cash flow, 12 months$85M$20.6B
Earnings per share, 12 months$0.80$6.59
Revenue growth, year on year-0.9%6.1%
Revenue growth a year, past+12.1%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

BVSJNJ
Margins and returns on capital
Gross margin68.7%67.6%
Operating margin9.7%–
Net margin9.8%16.2%
ROIC9.4%12.4%
ROE28.4%19.7%

Balance sheet

BVSJNJ
Balance sheet
Cash$31M$17.2B
Total debt$244M$44.7B
Net debt / EBITDA2.01.1
Interest cover–18.0×

Dividends and buybacks

BVSJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BVS or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Bioventus or Johnson & Johnson?

By market value, Johnson & Johnson ($681B) is about 977.1 times Bioventus ($697M), at today's prices.

How did BVS and JNJ stock do over the last 5 years?

Since November 12, 2021, BVS's price moved -32.7% and JNJ's +73.2%. With dividends: BVS -32.7% (-7.6% a year), JNJ +99.1% (+14.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, BVS or JNJ?

The dividend yield at today's price is none for Bioventus and 1.87% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Bioventus or Johnson & Johnson?

Over the last twelve months, the net margin was 9.8% for Bioventus and 16.2% for Johnson & Johnson, and the operating margin 9.7% and –. Revenue was $586M and $99.3B.

Which is the better investment, Bioventus or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.